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Background: Endothelial progenitor cells (EPCs), especially late EPCs, play a critical role in endothelial maintenance
and repair, and postnatal vasculogenesis. Advanced glycation end products (AGEs) have been shown to impair EPC
functions, such as proliferation, migration and adhesion. However, their role in the regulation of the production of
vasoactive substances in late EPCs is less well defined.
Methods: Passages of 3~5 EPCs, namely late EPCs, were cultured with different concentrations (0~500 μg/ml) of
AGEs, and the apoptosis, adhesion and migration were subsequently determined. The release of vasoactive
substances, such as stromal cell-derived factor-1 (SDF-1), nitric oxide (NO), prostaglandin I2 (PGI2), plasminogen
activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA), and in addition the activity of superoxide dismutase
(SOD), were evaluated by ELISA. At the same time, the gene and protein expressions of CXCR4 were assayed by
real-time RT-PCR and western-blot.
Results: AGEs promoted late EPC apoptosis. Moreover, AGEs impaired late EPC migration and adhesion in a
concentration-dependent manner. Accordingly, the production of SDF-1 was decreased by AGEs. Although the
CXCR4 expressions of late EPCs were up-regulated for AGE concentrations of 50, 100 or 200 μg/ml, a marked
decrease was observed for the higher concentration of 500 μg/ml. Furthermore, co-culturing with AGEs decreased
the levels of NO, t-PA, PGI2, and the activity of SOD but up-regulated the production of PAI-1.
Conclusion: Our data provide evidence that AGEs play an important role in impairing late EPC functions, which
could contribute to the development of vascular diseases in diabetes.
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Diabetes-associated cardiovascular complications, such as
atherosclerosis, myocardial infarction and stroke, are among
the major causes of patient mortality [1]. It has been shown
that loss of endothelial integrity contributes to vascular
complications of diabetes [2]. A growing body of evidence
indicates that endothelial regeneration and repair do not
exclusively rely on the proliferation of local endothelial
cells, but also involves bone marrow-derived endothelial
progenitor cells (EPCs) [3,4].
EPCs can be isolated from bone marrow, peripheral
blood, and umbilical cord blood. Recently, Naito et al even* Correspondence: chengmin1976@wfmc.edu.cn
†Equal contributors
Medicine Research Center, Weifang Medical College, Weifang, Shandong
261053, P. R. China
© 2012 Li et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the oridentified an endothelial progenitor/stem-like population
located at the inner surface of preexisting blood vessels [5].
Actually, EPCs are heterogeneous and can be classified at
least as early and late EPCs. The early EPCs appear within
4 to 7 days while the late EPCs develop after 2 to 3 weeks
in ex vivo culture systems. They share some endothelial
phenotype but are identified with different morphology,
proliferation rate and survival feature [6-8]. Currently, most
of the studies have mainly focused on early rather than late
EPCs [9,10]. However, late EPCs, which express a variety of
endothelial markers and functionally differentiate into
mature endothelial cells, seem to also be important in
promoting vascular integrity and neovascularization [11,12].
Advanced glycation end products (AGEs), which are
produced by the posttranslation modification of proteinshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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abundantly increase in case of diabetes. They have been
shown to be deposited in atherosclerotic lesion, and to
promote diabetes-accelerated atherosclerosis [13,14]. More-
over, AGEs impair cell–matrix interactions and growth
factor depletion [15]. These evidences suggest that the
increased formation of AGEs contributes, at least in part,
to the vascular damage in patients with diabetes. Recent
studies have shown that AGEs promote EPC apoptosis,
inhibit EPC proliferation, and impair EPC functions
such as migration, adhesion and tube-forming ability
[16,17]. However, growing evidence suggest that EPCs
can keep endothelial integrity not only by differentiating
into mature vascular endothelial cells, but also by secret-
ing the soluble factors including a number of enzymes
like matrix protein, growth factors and cytokines [18].
Although it would be interesting to examine the effects
of AGEs on the secretion actions of EPCs, only limited
studies have been conducted thus far. The present study
therefore aims to evaluate the role of AGEs in regulating
the release of vasoactive substances in late EPCs, such
as NO, PGI2, PAI-1, tPA, together with the activity of
SOD. At the same time, we also want to further confirm
the effects of AGEs on the apoptosis, migration and
adhesion of late EPCs, and to investigate the cellular basis,
in particular the role of the SDF-1/CXC4 system.
Methods
Bone marrow mononuclear cell isolation and culture
Whole bone marrow was isolated from both the femurs
and tibias of Sprague–Dawley rat (150 to 175 g) (Weifang
medical College, China). The bone marrow mononuclear
cells (MNCs) were fractionated by density gradient centri-
fugation (HistopaqueW-1083, Sigma, USA). MNCs were
plated on dishes precoated with 5% fibronectin (Roche,
Germany), and were maintained in complete EGM-2
medium (supplemented with EGM-2 bullet kit, including
5% fetal calf serum, recombinant rat VEGF, recombinant
human bFGF, Invitrogen, USA). After 4 days in culture,
unattached cells were removed by washing with PBS, after
which fresh medium was added. Endothelial colonies sub-
sequently appeared (on average 1 colony/107 or 108 plated
mononuclear cells). Highly proliferative endothelial cells
grew out from these colonies which then formed a conflu-
ent monolayer. Cells under passage 3~5, namely late EPCs,
were used for the present study [19]. All animal protocols
were approved by the local ethics committee at Weifang
Medical College.
EPC identification
After 7 days of culture, EPCs were characterized by the
uptake of 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindo-
carbocyanine–labeled acetylated low density lipoprotein
(Dil-acLDL, Molecular probes, USA), and by fluoresceinisothiocyanate labeled Ulex europaeus agglutinin (FITC-
UEA-1, Sigma, USA) staining. In short, the adherent
cells were first incubated with Dil-acLDL (2 μg/ml) for
1 h, after which they were fixed in 2% paraformaldehyde
for 10 min, and then stained with FITC-UEA-1 (10 μg/ml)
for 1 h. After the staining, the samples were viewed with
inverted fluorescence microscope (Leica, Germany). The
early EPCs were moreover confirmed by the expressions
of CD133 (eBioscience, USA, dilution 1:50) and Sca-1
(Becton Dickinson, USA, dilution 1:50). Cells under pas-
sage 3~5, namely late EPCs, were analyzed by FACS
(Becton Dickinson, USA) for the expressions of vWF
(Sigma, USA, dilution 1:200), VEGFR2 (eBioscience, USA,
dilution 1:100), VE-cadherin (Becton Dickinson, USA,
dilution 1:400) and PECAM-1(eBioscience, USA, dilution
1:100). The capability of EPCs to form capillary-like tubes
in vitro was assessed on Matrigel.
FACS analysis of apoptosis
Late EPCs were treated with AGEs (Biovision, USA) for
24 h. The range of AGE concentrations used in all experi-
ments was at a dose of 0~500 μg/ml which is representa-
tive of the plasma concentrations of AGEs found in
diabetic patients [20]. Approximately 1 × 106 cells were
double-stained with Annexin V-FITC and propidium
iodide (PI) by using apoptosis detection kit (Becton
Dickinson, USA) according to the manufacturer’s instruc-
tions. Apoptotic cells (Annexin V +/PI-) were detected by
FACS. The apoptotic percentage analysis was performed
using Cell-Quest software (Becton Dickinson, USA).
EPC migration assay
The migratory function of EPCs was evaluated by a modi-
fied Boyden chamber (Costar, Cambridge, MA, USA)
assay. Briefly, after incubation with serum-free medium for
6 h, EPCs were isolated with trypsin/EDTA, and then
incubated with serum-free medium containing AGEs. A
total of 4 × 104 EPCs were placed in the upper chamber
while medium with VEGF (50 ng/ml) was placed in the
lower chamber. The assays were conducted over a 24 h in-
cubation period at 37°C in an incubator equilibrated with
5% CO2. The membrane was then washed gently with
PBS, and fixed with 4% paraformaldehyde. Non-migrating
cells were gently removed with cotton balls from the upper
side of the membrane which was then stained by using
4′,6-diamidino-2-phenylindole (DAPI). The migration of
EPCs was evaluated by counting the migrated cells in six
random high-power (100×) microscope fields/well.
EPC adhesion assay
EPC adhesion assay were performed as previously described
[21]. After being treated with different concentrations of
AGEs for 24 h, EPCs were washed with PBS, and then gen-
tly detached with 0.25% trypsin/ EDTA. After centrifugation
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numbers were seeded on fibronectin coated culture dishes,
and incubated for 30 min at 37°C. Adherent cells were
counted independently in six random high-power (×100)
microscope fields (HPF)/well by three observers unaware
of the treatments.
Assay of the expressions of CXCR4 of EPCs by real-time
RT-PCR and western blot
Total cellular RNA was isolated with TRIzol reagent
(Invitrogen, USA) and reverse-transcribed to cDNA using
the SYBRW PrimeScriptW RT-PCR Kit (Takara, Japan) at
37°C for 15 min. Gene expressions were evaluated by
SYBRW Premix Ex Taq™ (Takara, Japan). Rat CXCR4 was
amplified with the sense primer 5′-AGC AGG TAG CAG
TGA CCC TCT GA-3′and the anti-sense primer: 5′-GAA
GCA GGG TTC CTT GTT GGA GT- 3′. GAPDH (sense
primer: 5′-GGC ACA GTC AAG GCT GAG AAT G- 3′,
anti-sense primer: 5′-ATG GTG GTG AAG ACG CCA
GTA- 3′) was used as a housekeeping gene, in order to
normalize the expression target gene. All primers were
used at a final concentration of 0.4 μmol/L. The thermal
cycling conditions were as follows: 30 seconds at 95°C for
pre-denaturation, 40 cycles for 15 seconds at 95°C for de-
naturation, 1 minute at 59°C for annealing, and 10 seconds
at 72°C for elongation. At the end of each cycle, the fluor-
escence emitted by the SYBR Green I was measured. After
completion of the cycling process, samples were immedi-
ately subjected to a temperature ramp for melting curve
analysis. The relative gene expression was analyzed by the
2-DDCt method [22].
Total cellular protein was extracted in 150 μl of
1 × SDS loading buffer (62.5 mmol/L Tris–HCl pH 6.8,
2% SDS, 10% glycerol, 50 mmol/L DTT, 0.1% bromphe-
nol blue) in the presence of 0.1% EDTA-free protease
inhibitor cocktail. Protein was quantified using the bicho-
ninic acid assay (BCA; Pierce Biotechnology, Rockford, IL,
USA) according to the manufacturer’s instructions. Equal
amounts of protein (50 μg) were separated through a 12%
SDS-PAGE, and transferred to a PVDF membrane. Mem-
branes were blocked in 5% milk-TBST, followed by over-
night incubation with the primary antibodies against
CXCR4. The membranes were then washed with TBST,
and incubated with secondary antibody conjugated to
HRP (Santa Cruz, USA, dilution 1:1000). Immunoreactive
bands were visualized by chemiluminenscence (ECL
Amersham Pharmacia).
Assay of secretion actions of EPCs
To measure the secretion actions of EPCs, the cultures
were washed and re-fed with equal amounts of serum-
free medium containing different concentrations of AGEs
for 24 h. The medium was collected and 10× concentrated
by centrifugation for 20 min at 5000× g at 4°C usingUltrafree-4 centrifugal filter tubes with Biomax-5 mem-
brane(Millipore, USA). The levels of SDF-1, NO, t-PA,
PAI-1, PGI2, and the activity of SOD in the cell culture
supernatants were measured by sandwich enzyme-linked
immunosorbent assay (ELISA, RD, USA) according to
the manufacturer’s instructions. Briefly, standard or test-
ing sample (50 μl) was added to the 96-well plate con-
taining immobilized monoclonal antibodies against a
kind of factor. After mixing by shaking gently, the plate
was incubated at 37°C for 30 min. The wells were then
washed five times, and incubated with HRP-conjugate
reagent at 37°C for 30 min. Afterwards, chromogen so-
lution A and chromogen solution B were added to each
well. The reaction was terminated after 20 min by add-
ing the stop solution. Blank well was taken as zero, and
the optical density (OD) was measured with an enzyme-
linked immunoabsorbent assay reader (Bio-Rad Labora-
tories, USA).
Statistical analyses
Unless otherwise indicated, results are reported as mean ±
SE from at least 4 independent experiments. Statistical
analyses were performed by one-way ANOVA, followed by
Tukey-Kramer post hoc test for multiple comparisons,
and p< 0.05 was considered to be statistically significant.
All data were analyzed using SPSS software (version 15.0;
SPSS, Chicago, IL, USA).
Results
Characterization of bone marrow-derived late EPCs
The bone marrow-derived MNCs that initially seeded
were round (Figure 1A). The distinct colonies formed
after 48 h, reaching a peak on the seventh day. The col-
onies of early EPCs appeared with the round cells in the
centers and the typical spindle cells at the peripheries
after 7 days (Figure 1B), and were identified as double-
positive for Dil-acLDL uptake and lectin binding affinity
(Figure 1D, E, F). Further FACS analysis revealed that
the respective expressions of CD133 and Sca-1 were
around 24.5% and 3.3% in early EPCs (Figure 1G). After
3~4 weeks, the 3~5 passage cells (late EPCs) showed char-
acteristic homogeneity and cobblestone-like morphology
similar to mature endothelial cells as previously reported
(Figure 1C) [23]. Moreover, the majority of the cells
expressed endothelial-specific markers: vWF, VEGFR-2,
VE-cadherin and PECAM-1 (Figure 1H) [10]. The angio-
genic property of the EPCs was also studied. As shown in
Figure 1I and Figure 1J, late, but not early, EPCs success-
fully formed tubuli like structures on Matrigel.
Effects of AGEs on late EPC apoptosis
Late EPCs were incubated with different concentrations
of AGEs (0, 50, 100, 200 and 500 μg/ml) for 24 h. As
shown in Figure 2, AGEs induced apoptosis in late EPCs.
Figure 1 Characterization of EPCs derived from bone marrow. A: MNCs were isolated and plated on fibronectin-coated culture dish on the
first day (100×). B: Seven days after plating, adherent early EPCs with spindle shape formed clones (100×). C: After 3~4 weeks, the third-fifth
passage cells (late EPCs) showed cobblestone-like morphology (100×). D-F: Most early EPCs were shown to simultaneously endocytose DiI-acLDL
(red) and bind fluorescein isothiocyanate UEA-1 (lectin) (100×). G: FACS analysis showing the expressions of CD133 and Sca-1 in early EPCs. Plots
show isotype controls (black) vs. specific antibody staining (red). H: FACS analysis showing the phenotype of late EPCs using several markers: vWF,
VEGFR-2, VE-cadherin and PECAM-1. Plots show isotype controls (black) vs specific antibody staining (red). I-J: Representative images of tubuli like
structures formed on Matrigel by early and late EPCs(100×).
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observed to increase with higher concentrations of AGEs,
reaching a peak at 100 μg/ml, and subsequently saturating
to a fixed value.
Effects of AGEs on late EPC migration, adhesion and
SDF-1/CXCR4 system
To examine the effects of AGEs on late EPC migration,
cells were treated for 24 h with different concentrations
of AGEs in the upper compartment of a Boyden chamber,
the lower compartment of which contained EBM-2 mediumwith VEGF. The AGEs were observed to inhibit late EPC
migration in a concentration-dependent manner, with a
4-fold decrease at the maximal concentration tested
(500 μg/ml, Figure 3A). Moreover, late EPC adhesion on
FN was also significantly reduced in a concentration-
dependent manner with adherent cells at less than 38%
of the control value when applied to the maximal dose
of AGEs (500 μg/ml, Figure 3B). To determine whether
the impaired migration and adhesion observed in AGE-
stressed EPCs was related to the SDF-1/CXCR4 system,
the release of SDF-1 was measured by ELISA. At the same
Annexin V
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Figure 2 Effects of AGEs on late EPC apoptosis. A: Late EPCs were incubated with different concentrations of AGEs (0, 50, 100, 200 and 500 μg/ml)
for 24 h. Harvested cells were stained with Annexin V FITC and PI, and quantified by FACS. Right lower quadrant means Annexin V positive and PI
negative. Right superior quadrant means Annexin V and PI positive. Left superior quadrant means Annexin V negative and PI positive. Left lower
quadrant means Annexin V and PI negative. Annexin V-positive and PI-negative cells were defined as apoptotic cells. B: The proportion of apoptotic
cells. Data represent the mean ± SE of four different experiments. *p< 0.05, **p< 0.01 vs. control.
Li et al. Cardiovascular Diabetology 2012, 11:46 Page 5 of 10
http://www.cardiab.com/content/11/1/46time, the mRNA and protein expressions of CXCR4 were
assessed by real-time RT-PCR and western blot, respect-
ively. The AGEs were found to induce a decrease in the
SDF-1 secretion in a dose-dependent manner (Figure 3C).
However, EPCs treated with 50, 100 and 200 μg/ml of
AGEs displayed higher mRNA and protein expressions of
CXCR4 than those in the untreated sample. Interestingly,
500 μg/ml of AGEs markedly decreased the CXCR4
mRNA and protein levels of late EPCs (Figure 3D, E).
Effects of AGEs on the productions of the vasodilators, NO
and PGI2, in late EPCs
To investigate the effects of AGEs on the productions of
the vasodilators in late EPCs, cells were incubated for
24 h in medium containing different concentrations of
AGEs (0~ 500 μg/ml). The cultured media were collected,
and the amounts of NO and PGI2 released from the late
EPCs were determined by ELISA. Given that PGI2 has a
short half-life (<20 minutes at physiological pH), levels of
6-keto-prostaglandin F1α (6-keto-PGF1α), the PGI2 stable
degenerative product, were quantified to evaluate the PGI2secretion from late EPCs. The results show that the incu-
bation of late EPCs with higher concentrations of AGEs
(200 and 500 μg/ml) significantly decreased the produc-
tion of NO, compared with that in the control medium.
For the lower concentrations of AGEs (50 and 100 μg/ml),
however, no such decrease was observed (Figure 4A). The
production of 6-keto-PGF1α by AGE-stressed EPCs was
reduced in a dose-dependent manner. (Figure 4B)
Role of AGEs on the activity of SOD in late EPCs
The bioactivity of SOD was measured in late EPCs. As
shown in Figure 5, incubation of cells with higher con-
centrations of AGEs decreased the SOD activity in EPCs
as compared to the control medium. The SOD activity
of EPCs was reduced by 25.9% and 43.7% in AGE con-
centrations of 200 and 500 μg/ml, respectively.
Influence of AGEs on PAI-1 and t-PA secretions from late
EPCs
Since the balance between PAI-1 and tPA determines the
fibrinolytic activity, we also investigated the effects of
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Figure 3 Effects of AGEs on late EPC migration, adhesion and SDF-1/CXCR4 system. Late EPCs were treated with different concentrations of
AGEs (0, 50, 100, 200, and 500 μg/ml) for 24 h. A: The modified Boyden chamber assay was used with VEGF as a chemoattractive factor for late EPC
migratory function. The migrated cells were stained with DAPI and counted under microscope. B: EPCs with equal cell numbers were seeded on
fibronectin coated culture dishes and incubated for 30 min at 37°C. Adherent cells were counted for late EPC adhesion function. C: The supernatants
were collected, and the content of SDF-1 was analyzed by ELISA. D: The CXCR4 mRNA expressions were determined using real time quantitative
RT-PCR. E: Cell lysates were resolved on 12% SDS-PAGE, followed by transfer to PVDF membrane. Western blot was carried out with specific
antibody for CXCR4, and each band was detected by the ECL reagent. In addition, the β-actin was analyzed as loading control and protein.
Data represent the mean ± SE of four different experiments. *p< 0.05, **p< 0.01 vs. control.
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EPCs. To this end, late EPCs were exposed to AGEs at
concentrations of 0~ 500 μg/ml for 24 h, after which they
were tested for PAI-1and tPA productions by ELISA. Incu-
bation of late EPCs with 500 μg/ml of AGEs led to a sig-
nificant decrease in the production of t-PA. However, no
statistically significant decrease was observed for low con-
centrations of AGEs (Figure 6A). In contrast, incubation
of late EPCs with 500 μg/ml AGEs led to an increase in
the production of PAI-1 (Figure 6B).
Discussion
AGEs,as a result of chronic hyperglycemia in diabetic
patients, have been identified as one of the key risk fac-
tors in diabetic-accelerated atherosclerosis [24]. Cell acti-
vation, proinflammatory cytokine release and oxidative
stress, induced by the interaction of AGEs with their
receptors, may lead to endothelial injury and dysfunction
[25,26]. Growing evidence suggests that EPCs, mobilized
from bone marrow and other sites, contribute to thestructural integrity of the vasculature, and also restore
endothelial dysfunction [3]. Recently, Palombo et al [27]
have reported that a significant reduction in the number
of EPCs is related to carotid intima-media thickness, an
induction of early atherosclerosis in diabetes mellitus.
Moreover, the frequency of EPCs in DM patients is
negatively correlated with the levels of hemoglobin AIc
(HbAIc) [28], and DM patients with satisfactory glycemic
control (defined by Hemoglobin A1c, HbA1c< 6.5%) have
been found to have significantly higher circulating EPC
counts [29]. On the contrary, reduction in circulating and
soluble form of AGEs by azelnidipine [30] may have bene-
ficial effects on glucose tolerance, insulin sensitivity, the
inflammatory state, and number of EPCs [31].
Sun et al [32] have reported that the receptors of
AGEs (RAGE) are expressed on EPCs at a low level in
normal conditions, and that AGEs significantly increase
the RAGE expression, and promote EPC apoptosis in a
dose-dependent manner (50~300 μg/ml). In agreement
with those findings, we have here shown that AGEs
Figure 4 Effects of AGEs on the productions of the vasodilators, NO and PGI2, in late EPCs. Late EPCs were incubated in medium
containing AGEs of concentrations between 0 ~ 500 μg/ml for 24 h, and the cultured media were then collected. A: The amount of NO was
determined by ELISA. B: The production of 6-keto-prostaglandin F1α (6-keto-PGF1α), the PGI2 stable degenerative product, was determined by
ELISA. Data represent the mean ± SE of four different experiments. *p< 0.05, **p< 0.01 vs. control.
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however, reaching peak at a concentration of 100 μg/ml,
after which it settles at a constant value even when the
AGE concentration is increased further. One possible
explanation for the differences between the observed re-
lationship between apoptosis rate and AGE concentra-
tion could be the different types of EPCs used in these
studies. Late EPCs were used in our study, while Sun
et al. used early EPCs in their experiments.
Previous investigations have also demonstrated that
AGEs impair EPC functions, such as migration, adhesion
and tube formation [16,17]. Our results further confirm
that AGEs inhibit migration and adhesion in late EPCs.
It is then natural to ask what the mechanisms behind
this might be. SDF-1 and its transmembrane receptor
























Figure 5 Role of AGEs on the activity of SOD in late EPCs. Late
EPCs were stimulated for 24 h with varying concentrations of AGEs
(0 ~ 500 μg/ml), and the cultured media were subsequently
collected. The SOD activity of late EPCs were assessed by ELISA.
Data represent the mean ± SE of four different experiments.
*p< 0.05, **p< 0.01 vs. control.immature stem cells [33,34]. Enhanced SDF-1 expression
and production is essential for the migration and adhe-
sion of stem cells [35]. It has been shown that ex vivo
exposure of EPCs to SDF-1 induces cell migration and
adhesion [36]. Moreover, Smadja et al [37] have demon-
strated that the angiogenic ability of EPCs may be
mediated by an autocrine mechanism involving SDF-1/
CXCR4. To characterize the role of the SDF-1/CXCR4
system in the AGE-induced decrease of the migration
and adhesion of late EPCs, we quantified the expressions
of SDF-1 and CXCR4. We have observed here that AGEs
induce a reduction in SDF-1. Intuitively, one could then
expect that AGEs might result in a decrease in CXCR4
as well. In our study, however, we found that AGEs led
to the CXCR4 overexpression on the late EPCs, with the
overexpression increasing as a function of the AGE con-
centration only up to a certain point (200 μg/ml), whereas
beyond this, at a very high concentration (500 μg/ml), the
CXCR4 expression levels were seen to decline. Thus the
elevated CXCR4 expression may account for a commen-
tary response to the defective SDF-1 in the AGE stressed-
EPCs while a high concentration of AGEs can destroy the
intrinsic commentary ability of late EPCs.
Due to the fact that the release of vasoactive factors by
EPCs also contributes to the vasculature integrity and
homeostasis [18], we explored in addition the influence
of AGEs on late EPC secretion functions. The results
show that AGEs cause a reduction in NO, PGI2 and tPA.
Furthermore, AGEs were identified to decrease the SOD
activity of EPCs. At high concentrations, however, the
AGEs were seen to increase the secretion of PAI-1 by
EPCs.
NO is a major vasodilator and a key survival factor of
the endothelium. The reduction in NO production is
possibly contributing to the development of endothelial
dysfunction and atherosclerosis in diabetes mellitus [38].


















































Figure 6 Influence of AGEs on PAI-1 and t-PA secretions from late EPCs. Late EPCs were exposed to AGEs at concentrations of 0 ~ 500 μg/ml
for 24 h, after which they were tested for t-PA (A) or PAI-1 (B) production by ELISA. Data represent the mean ± SE of four different experiments.
**p< 0.01 vs. control.
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cell niches to the peripheral circulation [39]. Moreover, it
has also been shown that the treatment of EPCs from
diabetes patients with an NO donor drug normalizes their
migration [40], and that SDF-1α restores EPC homing to
wounds in diabetic mice through an NO-dependent mech-
anism [41]. Urao et al have reported that transplantation
of autologous EPCs overexpressing eNOS in injured vessels
enhances the vasculoprotective prosperities of reconsti-
tuted endothelium [42]. Therefore, NO which is produced
by the EPCs themselves may create a favorable and optimal
environment in regulating their functions. Liang et al [21]
reported that the expression of phosphorylated-eNOS is
reduced by AGEs in EPCs. In line with this finding, our
results show that a 24 h incubation with AGEs significantly
decreases bioavailable NO of late EPCs, which would be
one of the determinants of vascular damage in diabetic
patients.
In addition to NO, PGI2 is not only a potent vasodilator
contributing to the protection and maintenance of homeo-
stasis in vasculature but also an inhibitor of platelet activa-
tion. It has been shown that PGI2 has a direct effect on
EPC functions in an autocrine or paracrine manner through
an NO-dependent mechanism, and EPCs from prostacyclin
receptor (IP−/−) mice fail to promote re-endothelialization
and vessel repair [43]. In the present study, our results
show that AGEs impair PGI2 release in cultured EPCs,
which may be one of the reasons why the levels of PGI2 is
low in the early stages of diabetes [44]. Furthermore,
decreased PGI2 has been linked to platelet hyperaggreg-
ability, increased adhesiveness, and increased release of
PGH2/TXA2 in diabetic patients [45].
It has become evident that the interaction between NO
and O2
- is important in the development of endothelial
dysfunction [46]. EPCs have high intracellular expression
levels of SOD, which can protect them against oxidativestress [47].Thum et al have reported that increased NAD
(P)H oxidase activity results in increased O2
- generation
and reduced NO bioavailability because O2
- inactivates NO
and uncouples eNOS in EPCs [48]. Moreover, the increased
O2
- is closely associated with the reduced extracellular SOD
activity [49]. Thus the addition of SOD may scavenge O2
-,
increase NO bioavailability and/or prevent the uncoupling
of eNOS in glucose-stressed EPCs [50].We have here
shown that AGEs dose-dependently inhibited SOD ac-
tivity, which may account for AGEs decreasing bioavail-
able NO of late EPCs. Thus, AGEs may increase the risk
of developing cardiovascular diseases by decreasing the
SOD activity of EPCs.
Clinical and experimental studies suggest that thrombus
formation and plaque rupture are other major aspects of
cardiovascular diseases [51]. t-PA is one of the most im-
portant fibrinolytic substances which regulates fibrinolytic
activity and prevents thrombus formation. Serving as the
primary inhibitor of t-PA, PAI-1 plays a critical role in the
regulation of fibrinolysis. The balance between these pro-
teins is known to control the development of thrombosis.
A recent study has shown that EPCs can also produce
t-PA, and that the amount secreted by EPCs is compar-
able to that secreted by mature endothelial cells [52].
Thus we have here also studied the effects of AGEs on
the secretion of t-PA and PAI-1 from late EPCs. We
have shown that incubation of late EPCs with high con-
centrations of AGEs leads to a significant decrease in
the production of t-PA, while increasing the production
of PAI-1. The different effects of AGEs on t-PA and
PAI-1 might lead to an imbalance between them, inducing
EPCs to become procoagulative and hypofibrinolytic.
Conclusion
Taken together, the present study demonstrates that
AGEs exert deleterious effects on EPC functions, such as
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dence that diabetes via AGEs may contribute to the
functional defects of the endothelium in pathological
situations by causing the dysfunction of EPCs. Further-
more, these findings give further insight into the com-
plex cellular mechanisms of EPCs for impaired vascular
repair and neovasculogenesis in diabetic patients.
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